174 related articles for article (PubMed ID: 38355807)
1. Targeted inhibition of SCF
Wang J; Ferrena A; Zhang R; Singh S; Viscarret V; Al-Harden W; Aldahamsheh O; Borjihan H; Singla A; Yaguare S; Tingling J; Zi X; Lo Y; Gorlick R; Schwartz EL; Zhao H; Yang R; Geller DS; Zheng D; Hoang BH
Oncogene; 2024 Mar; 43(13):962-975. PubMed ID: 38355807
[TBL] [Abstract][Full Text] [Related]
2. The interaction of SKP2 with p27 enhances the progression and stemness of osteosarcoma.
Wang J; Aldahamsheh O; Ferrena A; Borjihan H; Singla A; Yaguare S; Singh S; Viscarret V; Tingling J; Zi X; Lo Y; Gorlick R; Zheng D; Schwartz EL; Zhao H; Yang R; Geller DS; Hoang BH
Ann N Y Acad Sci; 2021 Apr; 1490(1):90-104. PubMed ID: 33594717
[TBL] [Abstract][Full Text] [Related]
3. SKP2 Knockout in Rb1/p53-Deficient Mouse Models of Osteosarcoma Induces Immune Infiltration and Drives a Transcriptional Program with a Favorable Prognosis.
Ferrena A; Wang J; Zhang R; Karadal-Ferrena B; Al-Hardan W; Singh S; Borjihan H; Schwartz EL; Zhao H; Oktay MH; Yang R; Geller DS; Hoang BH; Zheng D
Mol Cancer Ther; 2024 Feb; 23(2):223-234. PubMed ID: 37871911
[TBL] [Abstract][Full Text] [Related]
4. p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Zhao H; Lu Z; Bauzon F; Fu H; Cui J; Locker J; Zhu L
Oncogene; 2017 Jan; 36(1):60-70. PubMed ID: 27181203
[TBL] [Abstract][Full Text] [Related]
5. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
6. SKP2 knockout in Rb1/p53 deficient mouse models of osteosarcoma induces immune infiltration and drives a transcriptional program with a favorable prognosis.
Ferrena A; Wang J; Zhang R; Karadal-Ferrena B; Al-Hardan W; Singh S; Borjihan H; Schwartz E; Zhao H; Yang R; Geller D; Hoang B; Zheng D
bioRxiv; 2023 May; ():. PubMed ID: 37214958
[TBL] [Abstract][Full Text] [Related]
7. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.
Wang H; Bauzon F; Ji P; Xu X; Sun D; Locker J; Sellers RS; Nakayama K; Nakayama KI; Cobrinik D; Zhu L
Nat Genet; 2010 Jan; 42(1):83-8. PubMed ID: 19966802
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
[TBL] [Abstract][Full Text] [Related]
9. Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.
Gupta P; Zhao H; Hoang B; Schwartz EL
Br J Cancer; 2022 Oct; 127(6):969-975. PubMed ID: 35752713
[TBL] [Abstract][Full Text] [Related]
10. Deletions of Retinoblastoma 1 (Rb1) and Its Repressing Target S Phase Kinase-associated protein 2 (Skp2) Are Synthetic Lethal in Mouse Embryogenesis.
Zhao H; Wang H; Bauzon F; Lu Z; Fu H; Cui J; Zhu L
J Biol Chem; 2016 May; 291(19):10201-9. PubMed ID: 26966181
[TBL] [Abstract][Full Text] [Related]
11. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
Bochis OV; Irimie A; Pichler M; Berindan-Neagoe I
J Gastrointestin Liver Dis; 2015 Jun; 24(2):225-34. PubMed ID: 26114183
[TBL] [Abstract][Full Text] [Related]
12. Targeted pharmacologic inhibition of S-phase kinase-associated protein 2 (SKP2) mediated cell cycle regulation in lung and other RB-Related cancers: A brief review of current status and future prospects.
Elahi AH; Morales CS; Xu XL; Eliades A; Patsalis PC; Abramson DH; Jhanwar SC
Adv Biol Regul; 2023 May; 88():100964. PubMed ID: 37004354
[TBL] [Abstract][Full Text] [Related]
13. Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas.
Huang HY; Kang HY; Li CF; Eng HL; Chou SC; Lin CN; Hsiung CY
Clin Cancer Res; 2006 Jan; 12(2):487-98. PubMed ID: 16428491
[TBL] [Abstract][Full Text] [Related]
14. Substituting threonine 187 with alanine in p27Kip1 prevents pituitary tumorigenesis by two-hit loss of Rb1 and enhances humoral immunity in old age.
Zhao H; Bauzon F; Bi E; Yu JJ; Fu H; Lu Z; Cui J; Jeon H; Zang X; Ye BH; Zhu L
J Biol Chem; 2015 Feb; 290(9):5797-809. PubMed ID: 25583987
[TBL] [Abstract][Full Text] [Related]
15. NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2-p21/p27 axis.
Shen L; Qu X; Li H; Xu C; Wei M; Wang Q; Ru Y; Liu B; Xu Y; Li K; Hu J; Wang L; Ma Y; Li M; Lai X; Gao L; Wu K; Yao L; Zheng J; Zhang J
Oncogene; 2018 Mar; 37(13):1759-1774. PubMed ID: 29343851
[TBL] [Abstract][Full Text] [Related]
16. Specific small molecule inhibitors of Skp2-mediated p27 degradation.
Wu L; Grigoryan AV; Li Y; Hao B; Pagano M; Cardozo TJ
Chem Biol; 2012 Dec; 19(12):1515-24. PubMed ID: 23261596
[TBL] [Abstract][Full Text] [Related]
17. Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.
Huang KT; Pavlides SC; Lecanda J; Blank SV; Mittal KR; Gold LI
PLoS One; 2012; 7(9):e46072. PubMed ID: 23029392
[TBL] [Abstract][Full Text] [Related]
18. SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer.
Fagan-Solis KD; Pentecost BT; Gozgit JM; Bentley BA; Marconi SM; Otis CN; Anderton DL; Schneider SS; Arcaro KF
J Cell Physiol; 2014 Sep; 229(9):1160-9. PubMed ID: 24443386
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma.
Zhang Y; Zvi YS; Batko B; Zaphiros N; O'Donnell EF; Wang J; Sato K; Yang R; Geller DS; Koirala P; Zhang W; Du X; Piperdi S; Liu Y; Zheng D; Roth M; Gill J; Zhang J; Ren T; Gorlick R; Zi X; Hoang BH
Sci Rep; 2018 Sep; 8(1):14294. PubMed ID: 30250282
[TBL] [Abstract][Full Text] [Related]
20. Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity.
Lu Z; Bauzon F; Fu H; Cui J; Zhao H; Nakayama K; Nakayama KI; Zhu L
Nat Commun; 2014 Mar; 5():3463. PubMed ID: 24632684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
